These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18195551)

  • 1. [Adverse drug reactions induced by molecular target therapy].
    Kano Y
    Arerugi; 2007 Dec; 56(12):1485-91. PubMed ID: 18195551
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapeutic agents and the skin: An update.
    Heidary N; Naik H; Burgin S
    J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

  • 4. How to manage hypersensitivity reactions to biological agents?
    Barbaud A; Granel F; Waton J; Poreaux C
    Eur J Dermatol; 2011; 21(5):667-74. PubMed ID: 21742594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular targeting drugs].
    Ishikawa K
    Nihon Jinzo Gakkai Shi; 2012; 54(5):561-73. PubMed ID: 22991834
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists.
    Campi P; Benucci M; Manfredi M; Demoly P
    Curr Opin Allergy Clin Immunol; 2007 Oct; 7(5):393-403. PubMed ID: 17873578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
    Wallis RS; Broder MS; Wong JY; Hanson ME; Beenhouwer DO
    Clin Infect Dis; 2004 May; 38(9):1261-5. PubMed ID: 15127338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab.
    Puxeddu I; Giori L; Rocchi V; Bazzichi L; Bombardieri S; Tavoni A; Migliorini P; Del Corso I
    Ann Allergy Asthma Immunol; 2012 Feb; 108(2):123-4. PubMed ID: 22289732
    [No Abstract]   [Full Text] [Related]  

  • 9. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
    Kim R; Toge T
    Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 12. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
    Richette P; Viguier M; Bachelez H; Bardin T
    J Rheumatol; 2007 Feb; 34(2):438-9. PubMed ID: 17304662
    [No Abstract]   [Full Text] [Related]  

  • 13. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 15. Concern regarding the safety of tumor necrosis factor-alfa antagonists in pregnancy.
    Miner A
    J Am Acad Dermatol; 2010 Apr; 62(4):706. PubMed ID: 20227584
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphomatoid granulomatosis induced by imatinib-treatment.
    Yazdi AS; Metzler G; Weyrauch S; Berneburg M; Bitzer M; Müller-Hermelink HK; Röcken M
    Arch Dermatol; 2007 Sep; 143(9):1222-3. PubMed ID: 17875901
    [No Abstract]   [Full Text] [Related]  

  • 17. Inconsistencies in reporting of granulomatous infectious diseases associated with infliximab and etanercept.
    Schaible TF
    Clin Infect Dis; 2004 Oct; 39(8):1255-6; author reply 1256. PubMed ID: 15486858
    [No Abstract]   [Full Text] [Related]  

  • 18. Another look at imatinib mesylate.
    Strebhardt K; Ullrich A
    N Engl J Med; 2006 Dec; 355(23):2481-2. PubMed ID: 17151370
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al.
    Scrivo R; Spadaro A; Spinelli FR; Valesini G
    Arthritis Rheum; 2008 May; 58(5):1555-6; author reply 1556-7. PubMed ID: 18438848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.